Q2 26 EPS
$0.45
BEAT +18.70%
Est. $0.38
Q2 26 Revenue
$168.5M
BEAT +6.94%
Est. $157.6M
vs S&P Since Q2 26
-72.3%
TRAILING MARKET
DOCS -61.3% vs S&P +11.0%
Market Reaction
Did DOCS Beat Earnings? Q2 2026 Results
Doximity turned in a standout fiscal second quarter for 2026, posting revenue of $168.53 million, up 23.2% year-over-year and well ahead of the $157.59 million consensus, while non-GAAP diluted EPS of $0.45 beat the $0.38 estimate by 18.70%, reflecti… Read more Doximity turned in a standout fiscal second quarter for 2026, posting revenue of $168.53 million, up 23.2% year-over-year and well ahead of the $157.59 million consensus, while non-GAAP diluted EPS of $0.45 beat the $0.38 estimate by 18.70%, reflecting the kind of operating leverage that has become a hallmark of the physician network platform. The single most material driver behind the beat was margin expansion: adjusted EBITDA reached $100.83 million, pushing margins to 59.8% from 55.7% a year ago, as revenue acceleration outpaced cost growth. AI engagement was a notable catalyst, with AI Scribe and DoxGPT users growing over 50% from the prior quarter and a record 650,000 prescribers tapping Doximity's workflow tools, a dynamic that stands in contrast to other software companies struggling to translate strong results into investor confidence. Management raised full-year fiscal 2026 revenue guidance to $640–$646 million and guided Q3 revenue of $180–$181 million, signaling continued momentum through the seasonally important back half of the year.
Key Takeaways
- • Record 650,000 prescribers used workflow tools in Q2
- • AI Scribe and DoxGPT user growth over 50% quarter-over-quarter
- • 23% year-over-year revenue growth
- • Adjusted EBITDA margin expansion to 59.8% from 55.7% year-over-year
- • Non-GAAP net income margin expansion to 53.4% from 44.7% year-over-year
DOCS YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
DOCS Revenue by Segment
Business unit performance breakdown
“Our platform continues to grow with new AI tools to save physicians' time.”
— Jeff Tangney, Q2 2026 Earnings Press Release
DOCS Earnings Trends
DOCS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
DOCS EPS Trend
Earnings per share: estimate vs actual
DOCS Revenue Trend
Quarterly revenue: estimate vs actual
DOCS Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 26 MISS FY | $0.28 | $0.26 | -7.93% | $145.4M | +1.02% |
| FY Full Year | $1.55 | $1.52 | -1.72% | $644.9M | +0.20% |
| Q3 26 BEAT | $0.45 | $0.46 | +2.89% | $185.1M | +1.93% |
| Q2 26 BEAT | $0.38 | $0.45 | +18.70% | $168.5M | +6.94% |
| Q1 26 BEAT | $0.31 | $0.36 | +17.23% | $145.9M | +4.57% |
| Q4 25 BEAT FY | $0.27 | $0.38 | +39.25% | $138.3M | +3.20% |
| FY Full Year | $1.31 | $1.42 | +8.41% | $570.4M | +0.15% |